EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

7978 Metabolic Outcomes in Transgender Youth Receiving Affirming Hormonal Therapy

Mostafa Salama, Rami Basmaci, Tamim Rajjo, Olena Chuzhyk, Aida Nadim Lteif, Alaa Al Nofal

Journal of the Endocrine Society · 05.10.2024 · 8 (Supplement_1)

DOI: 10.1210/jendso/bvae163.1483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 05.10.2024. Verfasst von Mostafa Salama und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disclosure: M. Salama: None. R. Basmaci: None. T. Rajjo: None. O. Chuzhyk: None. A.N. Lteif: None. A. Al Nofal: None.

Objective

Heightened societal acceptance of transgender youth and increased awareness of their unmet medical needs have led to a rise in referrals for hormonal therapy. There is limited literature available on the metabolic outcomes of hormone therapy on transgender youth. We investigated how the different metabolic markers of cardiovascular disease change after the initiation of gender-affirming hormonal therapy in transgender adolescents.

Methods

A Retrospective, observational cohort study based on chart review of all children with gender dysphoria (under 18 years of age) who were evaluated in the Pediatric Endocrinology Clinic in a tertiary care center between January 2015 and December 2022. Children's demographic information, baseline weight, height, BMI, hematocrit, lipid profile, ALT, prolactin, and HbA1C levels were obtained before and after the initiation of gender-affirming hormonal therapy. The Wilcoxon signed-rank test was employed for paired analysis, while the chi-square test was used as appropriate.

Results

We identified 106 transgender youth who were included in the analysis, with a median age at the start of hormonal therapy of 16 years (IQR: 15-17); comprising 68 trans-males (64%) and 38 trans-females (36%). The median treatment duration was 34 months (IQR: 18-54). Among trans-males, ALT levels increased post-treatment (mean difference 6.851 U/L, p < 0.001), as did BMI Z scores (mean difference 0.257, p < 0.001) and LDL-C (mean difference 12.734 mg/dl, p = 0.002), triglycerides (mean difference 10.18 mg/dl, p = 0.009), non-HDL-C (mean difference 12.8 mg/dl, p = 0.002), and total cholesterol (mean difference 10.18 mg/dl, p = 0.02). No significant differences were observed in HbA1C and HDL-C post-treatment. Among transfemales, BMI Z-scores were higher post-treatment (mean difference 0.27, p = 0.007), with increased total cholesterol (mean difference 19.88 mg/dl, p = 0.008), LDL-C (mean difference 12.6 mg/dl, p = 0.02), and HDL-C (mean difference 11.38 mg/dl, p < 0.001). Other variables did not significantly differ pre-and post-treatment. Ten transfemales with measured prolactin levels pre- and post-treatment showed no statistically significant differences.

Conclusion

This pilot study revealed increased BMI Z scores following the commencement of hormone therapy in both trans-male and trans-female youths. Moreover, masculinizing treatment led to increased ALT levels. Furthermore, the cardiometabolic profile exhibited diverse alterations, particularly higher LDL-C levels in both cohorts. These findings underscore the necessity for close monitoring of these parameters during the treatment of transgender youth. Larger prospective randomized controlled trials are essential to comprehensively assess the impact of gender-affirming therapy on transgender youth. Presentation: 6/2/2024

Zitieren

APA

Salama, M., Basmaci, R., Rajjo, T., Chuzhyk, O., Lteif, A. N., & Nofal, A. A. (2024). 7978 Metabolic Outcomes in Transgender Youth Receiving Affirming Hormonal Therapy. Journal of the Endocrine Society, 8(Supplement_1). https://doi.org/10.1210/jendso/bvae163.1483

Vancouver

Salama M, Basmaci R, Rajjo T, Chuzhyk O, Lteif AN, Nofal AA. 7978 Metabolic Outcomes in Transgender Youth Receiving Affirming Hormonal Therapy. Journal of the Endocrine Society. 2024;8(Supplement_1). doi:10.1210/jendso/bvae163.1483

BibTeX
@article{Salama2024,
  author = {Salama, Mostafa and Basmaci, Rami and Rajjo, Tamim and Chuzhyk, Olena and Lteif, Aida Nadim and Nofal, Alaa Al},
  title = {7978 Metabolic Outcomes in Transgender Youth Receiving Affirming Hormonal Therapy},
  journal = {Journal of the Endocrine Society},
  year = {2024},
  volume = {8},
  number = {Supplement_1},
  doi = {10.1210/jendso/bvae163.1483}
}
Kostenlos starten →